Physician profile
Ryan Mack
NPI 1447516174
$1,733.73
in general payments reported to CMS, 2019-2025
24 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $105 · 2021: $72.98 · 2022: $244 · 2023: $163 · 2024: $340 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.70 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.02 | 2019-2025 | Lifevest |
| Pfizer INC. | $294.20 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $269.10 | 2019-2025 | |
| Amgen INC. | $126.43 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $93.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.56 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $54.32 | 2022-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $42.80 | 2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $41.83 | 2023-2025 | Barostim Neo System |
| Boston Scientific Corporation | $38.75 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $37.57 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $37.24 | 2021-2022 | |
| Amarin Pharma, INC. | $33.19 | 2019 | |
| Inspire Medical Systems, INC. | $31.28 | 2025 | Inspire |
| Heartflow, INC. | $29.99 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $26.46 | 2024 | Arcalyst |
| Astellas Pharma US INC | $25.98 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $23.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.30 | 2022 | |
| Scpharmaceuticals INC. | $18.22 | 2023 | |
| Biosense Webster, INC. | $17.48 | 2023 | Na |
| Edwards Lifesciences Corporation | $15.65 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $15.61 | 2022 | |
| Esperion Therapeutics, INC. | $13.85 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.